Last updated:
Author(s):
Chengxiao Yu, Yuchen Tang, Maojie Liu, Xin Xu, Xinyuan Ge, Hongxia Ma, Guangfu Jin, Hongbing Shen, Ci Song, Zhibin Hu
Publish date:
10 August 2024
Journal:
Journal of Gastroenterology
PubMed ID:
39126459

Abstract

BackgroundRecent genome-wide association studies (GWASs) in liver diseases have generated some polygenic risk scores (PRSs), but their predictive effectiveness on hepatocellular carcinoma (HCC) risk assessment remains unclear.MethodsHere, we constructed a novel combined polygenic risk score and evaluated its increment to the well-established risk model. We used 15 HCC-associated genetic loci from two PRSs and FinnGen GWAS data to calculate a PRS-combined score and to fit the related PRS model in the UK Biobank cohort (N = 436,162). The PRS-combined score was further assessed for risk stratification for HCC integrating with the recommended clinical risk scores.ResultsThe PRS-combined model achieved a better AUC (0.657) than that of PRS-HFC (0.637) and PRS-cirrhosis (0.645). The top 20% of the PRS-combined distribution had a 3.25 increased risk of HCC vs. the middle decile (45-55%). At the population level, the addition of PRS-combined to the CLivD score significantly increased the C-statistic (from 0.716 to 0.746) and provided a remarkable improvement in reclassification (NRI = 0.088) at the 10-year risk threshold of 0.2%. In clinic, additional assessment of PRS-combined would reclassify 34,647 intermediate-risk participants as high genetic risk, corresponding to an increase of 63.92% (62/97) of the HCC events classified at high risk using the Fibrosis-4 alone.ConclusionsThe PRS may enhance HCC risk prediction effectiveness in the general population and refine risk stratification of the conventional clinical indicator.

Related projects

Liver disease is increasing in the UK and around the world and is now a major cause of reduced quality of life and early death.

Institution:
Nanjing Medical University, China

All projects